HJC0152

HJC0152 is a novel, orally active small molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), developed by researchers at the University of Texas MD Anderson Cancer Center and the University of Texas Medical Branch. It was identified through fragment-based drug design to improve upon the potency, solubility, and bioavailability of earlier STAT3 inhibitors. HJC0152 functions by suppressing STAT3 promoter activity, inhibiting phosphorylation at the Y705 site, and reducing total STAT3 protein levels. Preclinical studies have demonstrated its efficacy in inducing cell growth arrest and apoptosis in ER-negative breast cancer and pancreatic cancer cell lines, as well as significantly reducing tumor growth in MDA-MB-231 breast cancer xenograft models.